Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of “Hold” from Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have received a consensus recommendation of “Hold” from the ten brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $9.33.

Several equities analysts recently weighed in on the company. Royal Bank of Canada downgraded Fulcrum Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price objective for the company from $15.00 to $4.00 in a research note on Thursday, September 12th. Leerink Partners reaffirmed a “market perform” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Thursday, September 12th. Bank of America cut Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and cut their price target for the stock from $10.00 to $2.00 in a report on Thursday, September 12th. Stifel Nicolaus lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and reduced their target price for the company from $22.00 to $3.00 in a report on Thursday, September 12th. Finally, HC Wainwright lowered shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $17.00 to $4.00 in a research report on Friday, September 13th.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of large investors have recently modified their holdings of FULC. National Bank of Canada FI boosted its position in shares of Fulcrum Therapeutics by 869.6% in the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock worth $28,000 after buying an additional 4,000 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Fulcrum Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock worth $43,000 after purchasing an additional 4,701 shares in the last quarter. Profund Advisors LLC acquired a new position in Fulcrum Therapeutics in the 2nd quarter worth $68,000. Renaissance Technologies LLC purchased a new position in Fulcrum Therapeutics in the second quarter valued at about $82,000. Finally, SG Americas Securities LLC purchased a new position in shares of Fulcrum Therapeutics during the 1st quarter valued at approximately $115,000. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Stock Performance

NASDAQ:FULC opened at $3.19 on Friday. Fulcrum Therapeutics has a 1 year low of $2.87 and a 1 year high of $13.70. The stock has a fifty day moving average price of $5.41 and a two-hundred day moving average price of $6.90. The stock has a market capitalization of $198.27 million, a price-to-earnings ratio of -1.99 and a beta of 2.21.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.87 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.93. The company had revenue of $80.00 million during the quarter, compared to analyst estimates of $80.00 million. During the same quarter last year, the business earned ($0.38) EPS. On average, analysts predict that Fulcrum Therapeutics will post -0.28 EPS for the current year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.